OBJECTIVE: To examine the effects of perioperative rhG-CSF administration on immune function in patients subjected to major surgery. SUMMARY BACKGROUND DATA: Severe trauma, such as major surgery, initiates acute immunodysfunction which predisposes the patient towards infectious complications. METHODS:Sixty patients undergoing elective surgery received either recombinant human granulocyte colony-stimulating factor/rh G-CSF (Filgrastim) or a placebo perioperatively. At several time points before and after the surgical intervention immunofunctional parameters were assessed. RESULTS Leukocyte counts and serum levels of anti-inflammatory mediators (IL-1ra and TNF-R) were increased in Filgrastim-treated patients, while the post-operative acute phase response was attenuated. Monocyte deactivation (reduced TNF-alpha release and HLA-DR expression) and lymphocyte anergy (impaired mitogenic proliferation and reduced TH1 lymphokine release) were blunted and the incidence and severity of infectious complications were reduced. CONCLUSIONS: These results suggest that Filgrastim treatment reinforces innate immunity, enabling better prevention of infection. Thus, this unique combination of hematopoietic, anti-inflammatory and anti-infectious effects on the innate immune system warrants further study of clinical efficacy and sepsis prophylaxis.
RCT Entities:
OBJECTIVE: To examine the effects of perioperative rhG-CSF administration on immune function in patients subjected to major surgery. SUMMARY BACKGROUND DATA: Severe trauma, such as major surgery, initiates acute immunodysfunction which predisposes the patient towards infectious complications. METHODS: Sixty patients undergoing elective surgery received either recombinant humangranulocyte colony-stimulating factor/rh G-CSF (Filgrastim) or a placebo perioperatively. At several time points before and after the surgical intervention immunofunctional parameters were assessed. RESULTS Leukocyte counts and serum levels of anti-inflammatory mediators (IL-1ra and TNF-R) were increased in Filgrastim-treated patients, while the post-operative acute phase response was attenuated. Monocyte deactivation (reduced TNF-alpha release and HLA-DR expression) and lymphocyte anergy (impaired mitogenic proliferation and reduced TH1 lymphokine release) were blunted and the incidence and severity of infectious complications were reduced. CONCLUSIONS: These results suggest that Filgrastim treatment reinforces innate immunity, enabling better prevention of infection. Thus, this unique combination of hematopoietic, anti-inflammatory and anti-infectious effects on the innate immune system warrants further study of clinical efficacy and sepsis prophylaxis.
Authors: T Hartung; S von Aulock; M Freitag; S Höxtermann; M Stücker; K Hoffmann; P Altmeyer; A Kottke; A Wendel Journal: Cytokine Date: 2000-10 Impact factor: 3.861
Authors: T Hartung; W D Doecke; D Bundschuh; M A Foote; F Gantner; C Hermann; A Lenz; S Milwee; B Rich; B Simon; H D Volk; S von Aulock; A Wendel Journal: Clin Pharmacol Ther Date: 1999-10 Impact factor: 6.875
Authors: Anja K Schröder; Maren von der Ohe; Ute Kolling; Julia Altstaedt; Peter Uciechowski; Daniela Fleischer; Klaus Dalhoff; Xinsheng Ju; Martin Zenke; Nicole Heussen; Lothar Rink Journal: Immunology Date: 2006-11 Impact factor: 7.397
Authors: Joshua S Jolissaint; Maya Harary; Lily V Saadat; Arin L Madenci; Bryan V Dieffenbach; Riad H Al Natour; Ali Tavakkoli Journal: J Gastrointest Surg Date: 2019-01-18 Impact factor: 3.452
Authors: Daniel Inderbitzin; Guido Beldi; Daniel Sidler; Peter Studer; Adrian Keogh; Sonja Bisch-Knaden; Rosy Weimann; Andreas Kappeler; Beat Gloor; Daniel Candinas Journal: J Gastrointest Surg Date: 2007-03 Impact factor: 3.452